
- /
- Supported exchanges
- / TA
- / TEVA.TA
Teva Pharmaceutical Industries Ltd (TEVA TA) stock market data APIs
Teva Pharmaceutical Industries Ltd Financial Data Overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Teva Pharmaceutical Industries Ltd data using free add-ons & libraries
Get Teva Pharmaceutical Industries Ltd Fundamental Data
Teva Pharmaceutical Industries Ltd Fundamental data includes:
- Net Revenue: 16 616 M
- EBITDA: 4 467 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Teva Pharmaceutical Industries Ltd News

Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Larry Robbins’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NY...


Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million
Teva Pharmaceutical Industries recently made headlines by agreeing to a $2.25 million settlement in a class-action lawsuit concerning Effexor XR®. This legal development, although not directly affect...

TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
Teva Pharmaceutical Industries TEVA reported first-quarter 2025 adjusted earnings of 52 cents per share, which beat the Zacks Consensus Estimate of 47 cents. Adjusted earnings rose 8% year over year, ...

Teva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Teva Pharmaceutical Industries (NYSE:TEVA) First Quarter 2025 Results Key Financial Results Revenue: US$3.89b (up 1.9% from 1Q 2024). Net income: US$214.0m (up from US$139.0m loss in 1Q 2024). Profi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.